Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort | Zendy

Jörg Janne Vehreschild | Zendy; Maria J. G. T. Rüping | Zendy; Hilmar Wisplinghoff | Zendy; Fedja Farowski | Zendy; Angela Steinbach | Zendy; Robert B. Sims | Zendy; A. Stollorz | Zendy; KarlAnton Kreuzer | Zendy; Michael Hallek | Zendy; Christopher Bangard | Zendy; Oliver A. Cornely | Zendy

Open Access

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort

Author(s) -

Jörg Janne Vehreschild,

Maria J. G. T. Rüping,

Hilmar Wisplinghoff,

Fedja Farowski,

Angela Steinbach,

Robert B. Sims,

A. Stollorz,

KarlAnton Kreuzer,

Michael Hallek,

Christopher Bangard,

Oliver A. Cornely

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq121

Subject(s) - posaconazole , medicine , aspergillosis , incidence (geometry) , surgery , clinical trial , antibiotic prophylaxis , antibiotics , antifungal , amphotericin b , immunology , dermatology , physics , microbiology and biotechnology , optics , biology

Large randomized controlled trials have shown significant decreases in morbidity and mortality in leukaemia patients with posaconazole prophylaxis. However, the value of prophylaxis has been questioned in centres with a low incidence of invasive fungal diseases (IFDs) and pre-emptive treatment strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research